Wave Life Sciences, Inc. (WVE)
WVENASDAQ-GMBiotechnology: Pharmaceutical Preparations
$3.41
-0.0700 (-2.01%) today
At the close, Nov 10, 4:00 PM ET. After hours $3.40 -0.29%
- Market cap
- $672.55m
- P/E
- –
- EPS, last 4 quarters
- $-1.07
- Dividend yield
- –
- Day range
- $3.32 to $3.55
- 52-week range
- $3.04 to $21.73
- Average volume
- 3.25m
- Previous close
- $3.48
Analysts
15 coveringBuy14 buy, 1 hold, 0 sell
Targets a year out average $16.70, +389.7% from here
Earnings
next estimate $-0.3300Next report
Dec 2025
-7.1%
Mar 2026
+61.8%
Jun 2026
-9.7%
Sep 2026
+11.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $17.25m | $38.25m | $2.27m | $13.16m |
| Gross profit | $17.25m | $38.25m | $2.27m | $13.16m |
| Operating income | -$56.47m | -$31.30m | -$73.80m | -$66.05m |
| Net income | -$53.18m | -$26.09m | -$69.36m | -$61.91m |
Last four quarters: revenue $70.92m, margin -296.9%, free cash flow -$208.39m
News
8 latest- Wave: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 1 day ago
- WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing ProgramMarketBeat · 6 days ago
- Biotech Stocks Move Higher: ZURA Surges 21%, PLUR Gains 13%, WVE Rises 7%, KNSA Advances RTTNews · Oct 27, 2026
- Wave Life Sciences (WVE) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 27, 2026
- WAVE Life Sciences Q3 Earnings Call HighlightsMarketBeat · Oct 27, 2026
- Wave Life Sciences Ltd. Reports Third Quarter 2026 Financial ResultsFintel · Oct 27, 2026
- Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue EstimatesZacks · Oct 27, 2026
- Wave Life Sciences Ltd. Q3 Sales Increase RTTNews · Oct 27, 2026
The company
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's PRISM platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's lead pipeline programs include obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), as well as several preclinical programs utilizing the company's versatile RNA medicines platform. Driven by the calling to 'Reimagine Possible,' Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Asia
- Website
- wavelifesciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.